90 related articles for article (PubMed ID: 20697802)
21. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
[TBL] [Abstract][Full Text] [Related]
22. Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.
Smith JW; Vukelja S; Rabe A; Wentworth-Hartung N; Koutrelakos N; Shao SH; Whittaker T; Wang Y; Asmar L; McDowell DO; Mukhopadhyay P; O'Shaughnessy J
Breast Cancer Res Treat; 2013 Nov; 142(2):381-8. PubMed ID: 24166282
[TBL] [Abstract][Full Text] [Related]
23. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
Addeo R; Faiola V; Guarrasi R; Montella L; Vincenzi B; Capasso E; Cennamo G; Rotundo MS; Tagliaferri P; Caraglia M; Del Prete S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
[TBL] [Abstract][Full Text] [Related]
24. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.
Schmid P; Kiewe P; Possinger K; Korfel A; Lindemann S; Giurescu M; Reif S; Wiesinger H; Thiel E; Kühnhardt D
Ann Oncol; 2010 Mar; 21(3):633-639. PubMed ID: 19880436
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.
Beer TM; Smith DC; Hussain A; Alonso M; Wang J; Giurescu M; Roth K; Wang Y
Br J Cancer; 2012 Aug; 107(5):808-13. PubMed ID: 22850553
[TBL] [Abstract][Full Text] [Related]
31. Ixabepilone: clinical role in metastatic breast cancer.
Denduluri N; Swain S
Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
[TBL] [Abstract][Full Text] [Related]
32. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
Campone M; Berton-Rigaud D; Joly-Lobbedez F; Baurain JF; Rolland F; Stenzl A; Fabbro M; van Dijk M; Pinkert J; Schmelter T; de Bont N; Pautier P
Oncologist; 2013; 18(11):1190-1. PubMed ID: 24105751
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
DeConti RC; Algazi AP; Andrews S; Urbas P; Born O; Stoeckigt D; Floren L; Hwang J; Weber J; Sondak VK; Daud AI
Br J Cancer; 2010 Nov; 103(10):1548-53. PubMed ID: 20924376
[TBL] [Abstract][Full Text] [Related]
35. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.
Araki K; Kitagawa K; Mukai H; Mukohara T; Kodama K; Ando Y; Narabayashi M; Minami H; Mera K; Sasaki Y
Invest New Drugs; 2012 Dec; 30(6):2327-33. PubMed ID: 22139065
[TBL] [Abstract][Full Text] [Related]
36. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.
Silvani A; Gaviani P; Fiumani A; Scaioli V; Lamperti E; Eoli M; Botturi A; Salmaggi A
J Neurooncol; 2009 Oct; 95(1):61-64. PubMed ID: 19381446
[TBL] [Abstract][Full Text] [Related]
37. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.
Yardley DA
Clin Breast Cancer; 2010 Feb; 10(1):64-73. PubMed ID: 20133261
[TBL] [Abstract][Full Text] [Related]
38. Epothilones in prostate cancer.
Kelly WK
Urol Oncol; 2011; 29(4):358-65. PubMed ID: 19914096
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy.
Diéras V; Limentani S; Romieu G; Tubiana-Hulin M; Lortholary A; Kaufman P; Girre V; Besenval M; Valero V
Ann Oncol; 2008 Jul; 19(7):1255-1260. PubMed ID: 18381372
[TBL] [Abstract][Full Text] [Related]
40. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
